The Search for New Drugs: Part I

The transcript discusses Novartis' R&D strategies, highlighting the challenges and advantages of being a large pharmaceutical company. It covers the importance of innovation, investment in gene and cell therapies, and the role of digital technology and AI in reducing costs. The conversation also touches on the pricing of gene therapies and the need for healthcare system adaptations. Additionally, it explores the potential return to antibiotics and the role of telemedicine in reaching new demand pockets.

In what ways does Novartis utilize digital technology to improve drug development processes?

What role does AI play in Novartis' operations, and what are its limitations?

How does Novartis address the need for a workforce skilled in data science and technology?

What are the implications of high pricing for gene therapies on healthcare systems?